Clinic spinoff starts trials on cardiovascular stem cell therapy
Juventas Therapeutics Inc.
By CHUCK SODER
2:56 pm, April 5, 2010
Juventas Therapeutics Inc., a Cleveland Clinic spinoff company, has started clinical trials on its cardiovascular stem cell therapy.
The Cleveland company this March started testing its lead product on patients suffering from Class III heart failure. Juventas aims to have tested the stem cell-based product on 16 patients by the end of the year, which would complete Phase I of the trial, CEO Rahul Aras said.
The product is designed to send a signal to stem cells within the body so that they migrate to the damaged tissue. The company?s animal studies suggest the therapy may promote cell survival and increase new blood vessel formation.
Juventas, which has raised nearly $10 million in venture capital since spinning off from the Clinic a few years ago, will have enough money to complete the trial?s first phase, Dr. Aras said.
http://www.crainscleveland.com/article/20100405/FREE/100409926
Juventas Therapeutics Inc.
By CHUCK SODER
2:56 pm, April 5, 2010
Juventas Therapeutics Inc., a Cleveland Clinic spinoff company, has started clinical trials on its cardiovascular stem cell therapy.
The Cleveland company this March started testing its lead product on patients suffering from Class III heart failure. Juventas aims to have tested the stem cell-based product on 16 patients by the end of the year, which would complete Phase I of the trial, CEO Rahul Aras said.
The product is designed to send a signal to stem cells within the body so that they migrate to the damaged tissue. The company?s animal studies suggest the therapy may promote cell survival and increase new blood vessel formation.
Juventas, which has raised nearly $10 million in venture capital since spinning off from the Clinic a few years ago, will have enough money to complete the trial?s first phase, Dr. Aras said.
http://www.crainscleveland.com/article/20100405/FREE/100409926